Ahn S S, Irie R F, Weisenburger T H, Jones P C, Juillard G, Roe D J, Morton D L
Surgery. 1982 Aug;92(2):362-7.
Since September 1979, 44 stage III melanoma patients treated with intralymphatic immunotherapy (ILI) with an oncofetal antigen (OFA-I)--enriched tumor cell vaccine (TCV) had evaluable humoral immune responses and clinical follow-up. Fourteen patients (32%) had stabilization or regression of tumors or remained free of resected disease. The median survival was 17 months, compared with 6 months for controls (P less than 0.001). Humoral immune responses were monitored by immune adherence using an OFA-positive human melanoma cell line, M14, as target. Alloantibodies were removed by absorption with L14 lymphoblasts autologous to M14. Twenty-two patients (50%) developed elevated antibody titers within 4 months, and 12 of the 22 (55%) had no disease progression. In contrast, 20 of 22 patients (91%) who failed to develop elevated titers had disease progression (P less than 0.01). The median titer was significantly higher during the first 4 months in the group whose disease did not progress (P less than 0.04). This study demonstrated that ILI with allogeneic OFA-I-enriched TCV can induce objective tumor regression and prolonged survival in patients with disseminated melanoma. Furthermore, because the specific humoral immune response correlates with clinical results, immunization efficacy can be monitored within a short period of time, which should aid future efforts to achieve optimal immunotherapy.
自1979年9月以来，44例接受了肿瘤胚胎抗原（OFA-I）富集肿瘤细胞疫苗（TCV）的淋巴内免疫疗法（ILI）治疗的III期黑色素瘤患者具有可评估的体液免疫反应并接受了临床随访。14例患者（32%）肿瘤稳定或消退，或切除术后无疾病复发。中位生存期为17个月，而对照组为6个月（P<0.001）。采用OFA阳性的人黑色素瘤细胞系M14作为靶细胞，通过免疫黏附监测体液免疫反应。用与M14自体的L14淋巴母细胞吸收去除同种抗体。22例患者（50%）在4个月内抗体滴度升高，其中12例（55%）无疾病进展。相比之下，22例未出现抗体滴度升高的患者中有20例（91%）出现疾病进展（P<0.01）。疾病未进展组在前4个月的中位滴度显著更高（P<0.04）。本研究表明，使用异体OFA-I富集TCV的ILI可诱导播散性黑色素瘤患者出现客观肿瘤消退并延长生存期。此外，由于特异性体液免疫反应与临床结果相关，可在短时间内监测免疫治疗效果，这将有助于未来实现最佳免疫治疗的努力。
